Published On : 11 june 2025
Published On : 11 june 2025
• The global Clinical Oncology NGS market was valued at approximately USD 704.70 million in 2023 and is projected to reach USD 1745.02 million by 2032, growing at a CAGR of 10.60%. North America remains a dominant player, with an estimated market size of USD 218.51 million in 2023, growing at a CAGR of 9.09% from 2025 through 2032.
Email: help@intelmarketresearch.com +91 9169164321
• Clinical Oncology Next Generation Sequencing (NGS) refers to advanced genetic sequencing technologies used to analyze various types of genetic mutations, including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes, and translocations. These technologies play a crucial role in precision medicine, allowing for targeted cancer therapies and personalized treatment approaches.
Email: help@intelmarketresearch.com +91 9169164321
•NGS Pre-Sequencing
•Sequencing
•NGS Data Analysis
•Primary, Secondary & Tertiary Data Analysis
